Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8826791 | 0.84 | ACHE (0.46) | KDM4EACHEL3MBTL1PLA2G2ATSHR | |
| SCHEMBL6792682 | 0.82 | TSHR (0.45) | TSHRMEN1POLBKMT2AHTT | |
| SCHEMBL3489028 | 0.80 | S1PR1 (0.41) | KDM4EL3MBTL1PLA2G2ATSHRPOLB | |
| SCHEMBL2245662 | 0.79 | LMNA (0.40) | KDM4EL3MBTL1PLA2G2ATSHRMEN1 | |
| SCHEMBL8803997 | 0.78 | PLA2G2A (0.47) | ACHEPLA2G2AGBA1ALDH1A1 | |
| SCHEMBL15548838 | 0.74 | KDM4E (0.41) | KDM4ETSHRMEN1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL31710101 | 0.73 | LMNA (0.41) | KDM4ETSHRPOLBKMT2AHTT | |
| SCHEMBL10718524 | 0.71 | L3MBTL1 (0.42) | ACHEL3MBTL1PLA2G2APOLBHTT | |
| SCHEMBL10285400 | 0.70 | LMNA (0.41) | KDM4ETSHRMEN1POLBKMT2A | |
| SCHEMBL15460601 | 0.69 | GAA (0.39) | KDM4EACHEL3MBTL1PLA2G2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101068772-A | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARM INC (US) | 2007-11-07 | — | — | CN | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1409450-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | KDM4E 2492/4885ACHE 58/4885L3MBTL1 2535/4885 |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | BACE1, APP, BACE2 | KDM4E 2392/4885ACHE 56/4885L3MBTL1 2539/4885 |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | BACE1, APP, BACE2 | KDM4E 2392/4885ACHE 56/4885L3MBTL1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.